-- ============================================================================
-- SURGERY 3 MCQ BATCH 27: Gastric Disorders (Questions 1561-1620)
-- Topic: Gastric Cancer, Gastric Ulcers, Gastric Outlet Obstruction
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Gastric Cancer (1-30)
('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'The most common type of gastric cancer is:',
'Lymphoma', 'Adenocarcinoma (90-95% of gastric malignancies)', 'GIST', 'Carcinoid', 'Sarcoma',
'B', 'Gastric cancer types: Adenocarcinoma 90-95% (most common). Others: lymphoma (MALT, diffuse large B-cell), GIST, carcinoid, leiomyosarcoma. Adenocarcinoma incidence declining in West but remains common in East Asia (Japan, Korea, China). Reference: Ajani JA. J Clin Oncol. 2017.',
'easy', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Major risk factors for gastric adenocarcinoma include:',
'Diet only', 'Helicobacter pylori infection, atrophic gastritis, intestinal metaplasia, smoking, and dietary factors (salted/smoked foods)', 'Young age only', 'Exercise', 'Vitamin C',
'B', 'Gastric cancer risk factors: (1) H. pylori infection (strongest, 4-6× risk, chronic gastritis → atrophy → intestinal metaplasia → dysplasia → cancer), (2) Atrophic gastritis (pernicious anemia), (3) Previous gastric surgery (15-20 years later), (4) Dietary: high salt, smoked/pickled foods, low fruits/vegetables, (5) Smoking, (6) Familial - hereditary diffuse gastric cancer (CDH1 mutation), (7) Adenomatous polyps >2cm. Reference: Karimi P. Gut. 2014.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Lauren classification divides gastric adenocarcinoma into:',
'Only one type', 'Intestinal (gland-forming, better prognosis) and diffuse (signet-ring cells, worse prognosis) types', 'Benign and malignant', 'Early and late', 'Proximal and distal',
'B', 'Lauren classification: (1) Intestinal type (54%) - gland-forming, resembles colon cancer, associated with H. pylori/atrophic gastritis/intestinal metaplasia, older age, better prognosis, more common distally. (2) Diffuse type (32%) - poorly cohesive, signet-ring cells, infiltrative (linitis plastica), younger age, worse prognosis, hereditary forms, less H. pylori association. (3) Mixed (14%). Reference: Lauren P. Acta Pathol Microbiol Scand. 1965.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Early gastric cancer is defined as:',
'Any small tumor', 'Cancer confined to mucosa or submucosa, regardless of lymph node status', 'Advanced disease', 'Metastatic', 'Polyp only',
'B', 'Early gastric cancer (EGC): confined to mucosa (T1a) or submucosa (T1b), regardless of lymph node involvement. Excellent prognosis (5-year survival >90%). More common in Japan (screening programs). May be amenable to endoscopic resection (EMR/ESD) if: mucosal only, <2cm, well-differentiated, no ulceration, no lymphovascular invasion. Advanced gastric cancer: invades muscularis propria or beyond. Reference: Gotoda T. Gastric Cancer. 2000.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Common presenting symptoms of gastric cancer include:',
'Asymptomatic only', 'Vague epigastric discomfort, weight loss, early satiety, anorexia (often late presentation)', 'Severe pain always', 'Diarrhea only', 'Fever',
'B', 'Gastric cancer presentation: Often late/non-specific. (1) Epigastric pain/discomfort (most common, mimics PUD), (2) Weight loss (significant, involuntary), (3) Early satiety (tumor/linitis plastica), (4) Nausea/vomiting (outlet obstruction), (5) Anorexia, (6) Dysphagia (proximal tumors), (7) GI bleeding (occult or overt - melena, hematemesis). Physical exam: palpable mass (advanced), ascites, Virchow node (left supraclavicular), Sister Mary Joseph node (umbilical), Blumer shelf (rectal exam - peritoneal drop metastases). Reference: Ajani JA. J Clin Oncol. 2017.',
'easy', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Virchow node refers to:',
'Right axillary adenopathy', 'Left supraclavicular lymphadenopathy indicating metastatic gastric or intra-abdominal malignancy', 'Inguinal node', 'Cervical node only', 'Normal finding',
'B', 'Virchow node (Troisier sign): palpable left supraclavicular lymph node, classic sign of metastatic intra-abdominal malignancy (gastric, pancreatic, ovarian). Spread via thoracic duct. Indicates advanced disease. Other metastatic signs: Sister Mary Joseph node (periumbilical), Irish node (left axillary), Blumer shelf (pelvic peritoneal implants), Krukenberg tumor (ovarian metastases). Reference: Riihimäki M. Int J Cancer. 2016.',
'easy', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Initial diagnostic workup for suspected gastric cancer includes:',
'Biopsy only', 'Upper endoscopy with multiple biopsies and CT chest/abdomen/pelvis for staging', 'No imaging', 'Surgery first', 'Observation',
'B', 'Gastric cancer workup: (1) Upper endoscopy (EGD) - visualization, multiple biopsies (6-10 from ulcer/mass edges and base), location, extent. (2) CT chest/abdomen/pelvis with oral/IV contrast - staging (local extent, lymph nodes, liver metastases, peritoneal disease, distant spread). (3) Endoscopic ultrasound (EUS) - T/N staging for potentially resectable tumors. (4) PET-CT - may detect occult metastases. (5) Diagnostic laparoscopy for locally advanced disease (assess peritoneal metastases, peritoneal washing cytology). Labs: CBC (anemia), tumor markers (CEA, CA 19-9). Reference: NCCN Guidelines. 2023.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'The role of endoscopic ultrasound (EUS) in gastric cancer includes:',
'Screening only', 'Assessment of depth of invasion (T stage) and regional lymph nodes (N stage) for resectability determination', 'Treatment', 'Diagnosis only', 'Not useful',
'B', 'EUS in gastric cancer: most accurate for locoregional staging. (1) T staging - depth of invasion through gastric wall layers (T1-T4), (2) N staging - regional lymph node assessment (size, shape, echo pattern, FNA if needed), (3) Determines resectability, (4) Guides treatment (endoscopic resection vs surgery vs neoadjuvant therapy). Accuracy: T stage 65-92%, N stage 50-90%. Less accurate after neoadjuvant therapy (inflammation). Reference: Mocellin S. J Surg Oncol. 2011.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'The surgical procedure for distal gastric cancer is:',
'Total esophagectomy', 'Subtotal (distal) gastrectomy with Billroth II or Roux-en-Y reconstruction', 'Whipple procedure', 'Only biopsy', 'No surgery available',
'B', 'Gastric cancer surgery - distal tumors: Subtotal/distal gastrectomy (remove distal 2/3-4/5 stomach) with 4-5 cm proximal margin. Reconstruction: Billroth II (gastrojejunostomy) or Roux-en-Y gastrojejunostomy (preferred - decreases bile reflux). D2 lymphadenectomy (perigastric + second tier nodes) standard in East, controversy in West. Proximal/diffuse tumors: total gastrectomy with esophagojejunostomy (Roux-en-Y). Reference: Japanese Gastric Cancer Treatment Guidelines. 2018.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'D2 lymphadenectomy in gastric cancer involves:',
'No lymph node removal', 'Removal of perigastric (D1) and second-tier lymph nodes along major vessels', 'Only one node', 'Inguinal nodes', 'Axillary nodes',
'B', 'Lymphadenectomy in gastric cancer: D1 - perigastric nodes along lesser/greater curvature. D2 - D1 plus nodes along left gastric artery, common hepatic artery, celiac axis, splenic artery. D2 standard in East Asia, improves staging, possible survival benefit. Controversy in West (higher morbidity in early Western trials, but improved with surgeon experience). At least 15-16 lymph nodes should be examined for adequate staging. Reference: Songun I. Lancet Oncol. 2010.',
'hard', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Perioperative chemotherapy (FLOT regimen) for gastric cancer:',
'Has no role', 'Improves survival when given before and after surgery for locally advanced resectable tumors', 'Is only postoperative', 'Is contraindicated', 'Only for metastatic disease',
'B', 'Perioperative chemotherapy: standard for locally advanced resectable gastric cancer (T2 or higher, any N). Regimens: FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) preferred - superior to ECF/ECX. Given preoperatively (3 cycles) and postoperatively (3 cycles). FLOT-4 trial: improved survival vs ECF/ECX. Alternative: postoperative chemoradiation (INT0116/MacDonald trial) if no neoadjuvant therapy. Metastatic disease: palliative chemotherapy (may include trastuzumab if HER2+). Reference: Al-Batran SE. Lancet. 2019.',
'hard', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'HER2 testing in gastric cancer is important because:',
'No therapeutic implication', 'HER2-positive tumors (10-20%) can be treated with trastuzumab (anti-HER2 therapy)', 'All are HER2 positive', 'HER2 is never positive', 'Testing not done',
'B', 'HER2 in gastric cancer: overexpressed/amplified in 10-20% (more common in intestinal type, GE junction tumors). ToGA trial: trastuzumab (Herceptin, anti-HER2 antibody) + chemotherapy improved survival in HER2+ metastatic gastric/GE junction cancer. HER2 testing mandatory for metastatic disease. IHC 3+ or IHC 2+/FISH+ = HER2 positive. Emerging: other HER2-directed therapies (pertuzumab, trastuzumab deruxtecan). Reference: Bang YJ. Lancet. 2010.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Linitis plastica refers to:',
'A benign gastric polyp', 'Diffuse infiltrative gastric cancer causing rigid, non-distensible stomach ("leather bottle")', 'Normal stomach', 'Gastric varices', 'Peptic ulcer',
'B', 'Linitis plastica ("leather bottle stomach"): diffuse infiltration of gastric wall by poorly differentiated adenocarcinoma (often signet-ring cells). Entire wall thickened and rigid, loss of distensibility. Barium study: non-distensible stomach with loss of rugae. Often T4 at presentation. Poor prognosis. May be primary gastric or metastatic (breast, lung). Associated with hereditary diffuse gastric cancer (CDH1 mutation). Reference: Hyngstrom JR. J Gastrointest Surg. 2012.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Hereditary diffuse gastric cancer (HDGC) syndrome is associated with:',
'APC mutation', 'CDH1 (E-cadherin) germline mutation with high risk of diffuse gastric cancer', 'BRCA1', 'P53 only', 'No genetic component',
'B', 'HDGC: autosomal dominant. CDH1 germline mutation → loss of E-cadherin (cell adhesion protein). Lifetime gastric cancer risk 70-80% (men), 56% (women). Women also increased lobular breast cancer risk (42-55%). Diffuse-type gastric cancer, young age (<40), multifocal signet-ring cells. Management: prophylactic total gastrectomy recommended age 20-30 (after CDH1 mutation confirmed, or by age 40 at latest). Screening ineffective (flat lesions). Reference: van der Post RS. Lancet Oncol. 2015.',
'hard', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Prognosis in gastric cancer is most influenced by:',
'Patient age only', 'Stage at diagnosis (depth of invasion, lymph node involvement, distant metastases)', 'Gender', 'Blood type', 'Diet',
'B', 'Gastric cancer prognosis: Stage most important. 5-year survival: Stage IA (T1N0) >90%, Stage IB-IIA 70-80%, Stage IIB-IIIA 30-60%, Stage IIIB-IIIC 10-25%, Stage IV (metastatic) <5%. Other factors: location (proximal worse), histology (diffuse worse), resection margins (R0 vs R1/R2), lymph node ratio, response to neoadjuvant therapy. Overall 5-year survival ~30% (all stages). Better in East Asia (earlier detection). Reference: SEER database. 2023.',
'medium', 'knowledge'),

-- Gastric Lymphoma (16-20)
('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'MALT lymphoma (mucosa-associated lymphoid tissue) of the stomach:',
'Requires immediate gastrectomy', 'Is associated with H. pylori infection and often regresses with H. pylori eradication', 'Is always metastatic', 'Has no treatment', 'Is unrelated to infection',
'B', 'Gastric MALT lymphoma: low-grade B-cell lymphoma arising from MALT. Strongly associated with chronic H. pylori gastritis (>90%). Localized disease (stage IE, IIE1): H. pylori eradication first-line - leads to complete remission in 60-80% of cases. Monitor with endoscopy/biopsy. If persistent or H. pylori-negative: radiation therapy. Surgery rarely needed (perforation, bleeding). Advanced disease: chemotherapy. Excellent prognosis. Reference: Zullo A. Gut. 2010.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Primary gastric lymphoma comprises what percentage of gastric malignancies:',
'<1%', 'About 3-5% (most common extranodal lymphoma site)', '50%', '90%', 'Never occurs',
'B', 'Gastric lymphoma: 3-5% of gastric malignancies. GI tract most common extranodal lymphoma site, stomach most common GI site (50-60% of GI lymphomas). Types: MALT (low-grade B-cell, 50-60%), diffuse large B-cell lymphoma (DLBCL, 30-40%), others. Diagnosis: endoscopy with deep biopsies. Staging: CT, endoscopic ultrasound. Treatment: MALT - H. pylori eradication; DLBCL - chemotherapy ± radiation. Surgery for complications. Reference: Zullo A. Gut. 2010.',
'medium', 'knowledge'),

-- GIST (21-28)
('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Gastrointestinal stromal tumors (GIST) arise from:',
'Epithelial cells', 'Interstitial cells of Cajal (pacemaker cells) or their precursors', 'Lymphocytes', 'Neurons', 'Endothelial cells',
'B', 'GIST: mesenchymal tumors from interstitial cells of Cajal (ICC) or stem cells. Most common site: stomach (60%), followed by small intestine (30%). Characterized by KIT (CD117) expression (95%) or PDGFRA mutations. Range from benign to malignant. Risk stratification based on size, mitotic rate, location. Reference: Miettinen M. Semin Diagn Pathol. 2006.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'GIST is characterized immunohistochemically by:',
'Keratin positivity', 'CD117 (c-KIT) positivity in 95% of cases', 'CD20 positivity', 'TTF-1 positivity', 'No markers',
'B', 'GIST markers: CD117 (c-KIT) positive in 95% - tyrosine kinase receptor, diagnostic marker. DOG1 (discovered on GIST) - positive in 95%, helpful in KIT-negative cases. CD34 positive in 70%. Most have KIT or PDGFRA activating mutations. Negative for: cytokeratin, S100 (distinguish from leiomyoma, schwannoma). Diagnosis: morphology + IHC. Reference: Corless CL. J Clin Oncol. 2011.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Clinical presentation of gastric GIST includes:',
'Always asymptomatic', 'GI bleeding (most common), abdominal pain, palpable mass, or incidental finding', 'Diarrhea only', 'Jaundice', 'Fever only',
'B', 'GIST presentation: (1) GI bleeding (most common) - acute or chronic, ulceration of overlying mucosa, (2) Abdominal pain/discomfort, (3) Early satiety, (4) Palpable mass (large tumors), (5) Incidental finding on imaging/endoscopy (small tumors), (6) Bowel obstruction (small intestine GIST). Rarely perforation. Can be asymptomatic. CT: enhancing mass, may have cystic/necrotic areas. Reference: Joensuu H. Lancet Oncol. 2012.',
'easy', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Treatment of localized GIST is:',
'Chemotherapy', 'Complete surgical resection with negative margins (R0 resection)', 'Radiation', 'Observation', 'Antibiotics',
'B', 'Localized GIST treatment: surgical resection - goal R0 resection with negative microscopic margins (tumor pseudocapsule intact). No lymphadenectomy needed (lymph node metastases rare). Wide local excision, may need partial gastrectomy. Avoid tumor rupture (increases recurrence). Laparoscopic approach feasible for small tumors. Neoadjuvant imatinib considered for borderline resectable or large tumors (shrink, facilitate resection). Reference: NCCN Guidelines. 2023.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Imatinib (Gleevec) in GIST:',
'Is not effective', 'Is a tyrosine kinase inhibitor targeting KIT/PDGFRA, used for metastatic, recurrent, or high-risk resected GIST', 'Only for diagnosis', 'Is an antibiotic', 'Has no role',
'B', 'Imatinib: tyrosine kinase inhibitor (TKI) targeting KIT and PDGFRA. Revolutionary for GIST treatment. Indications: (1) Metastatic/unresectable GIST (first-line), (2) Adjuvant therapy for high-risk resected GIST (≥3 years reduces recurrence), (3) Neoadjuvant (borderline resectable). Dramatic response in most patients (partial response 40-70%, stable disease 20-30%). Resistance develops (secondary KIT mutations) - use sunitinib (second-line), regorafenib (third-line), or other TKIs. Mutation analysis guides therapy. Reference: Joensuu H. Lancet Oncol. 2012.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Risk stratification for GIST malignancy is based on:',
'Age only', 'Tumor size, mitotic rate (per 50 HPF), and anatomic location', 'Color', 'Weight', 'Blood type',
'B', 'GIST risk stratification (modified NIH criteria): based on (1) Size (≤2cm, 2-5cm, 5-10cm, >10cm), (2) Mitotic rate (≤5, 6-10, >10 per 50 HPF), (3) Location (gastric better prognosis than small bowel). Categories: very low, low, intermediate, high risk of progressive disease. High-risk: large size + high mitotic rate, or tumor rupture, or small bowel location with high-risk features. Guides adjuvant imatinib decisions. Reference: Joensuu H. Lancet Oncol. 2012.',
'hard', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'GIST most commonly metastasizes to:',
'Brain', 'Liver and peritoneum', 'Bone', 'Lymph nodes', 'Skin',
'B', 'GIST metastases: (1) Liver (most common site, hematogenous), (2) Peritoneum (peritoneal seeding). Lymph node metastases rare (<5%). Lung metastases uncommon. Recurrence most common in first 5 years. PET-CT useful for response assessment (metabolic response precedes size change). Resection of oligometastatic disease considered if controlled on imatinib. Reference: DeMatteo RP. Ann Surg. 2009.',
'medium', 'knowledge'),

-- Other Gastric Conditions (29-60)
('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Gastric outlet obstruction (GOO) most commonly results from:',
'Normal anatomy', 'Peptic ulcer disease (duodenal ulcer scarring) or gastric malignancy', 'Infection only', 'Diet', 'Age',
'B', 'GOO causes: (1) Benign - peptic ulcer disease (duodenal ulcer scarring/edema) most common historically, now less common with PPI therapy; also: caustic ingestion, pancreatitis, Crohn disease, (2) Malignant - gastric cancer, pancreatic cancer. Pediatric: pyloric stenosis, duodenal web. Presentation: postprandial vomiting, early satiety, weight loss, dehydration. Succussion splash. Labs: hypochloremic hypokalemic metabolic alkalosis. Reference: Shone DN. Am J Gastroenterol. 1995.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'The metabolic derangement typically seen with gastric outlet obstruction is:',
'Metabolic acidosis', 'Hypochloremic, hypokalemic metabolic alkalosis', 'Respiratory acidosis', 'No derangement', 'Hyperkalemia',
'B', 'GOO metabolic effects: vomiting → loss of gastric secretions (HCl, K+) → hypochloremic, hypokalemic metabolic alkalosis. Paradoxical aciduria (kidneys retain H+ to preserve K+ despite alkalosis). Volume depletion, prerenal azotemia. Treatment: aggressive IV fluid/electrolyte repletion (NS with KCl) before definitive treatment. NG decompression. Reference: Gumaste VV. Am J Gastroenterol. 1996.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Diagnosis of gastric outlet obstruction includes:',
'Only clinical exam', 'Upper endoscopy (evaluate cause, biopsy) and CT abdomen/pelvis', 'No imaging', 'Colonoscopy', 'Ultrasound only',
'B', 'GOO diagnosis: (1) Clinical: nausea, vomiting (large volume, undigested food), weight loss, succussion splash, visible peristalsis, (2) Upper GI series: gastric distention, delayed emptying, (3) Upper endoscopy - directly visualize obstruction, biopsy (malignancy vs benign), dilation if benign stricture, (4) CT abdomen/pelvis - assess for malignancy, mass effect, complications. Labs: metabolic alkalosis, electrolyte abnormalities. Reference: Shone DN. Am J Gastroenterol. 1995.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Management of benign gastric outlet obstruction includes:',
'Observation only', 'Initial conservative management (NG decompression, fluids, PPI, nutrition), followed by endoscopic dilation or surgery if needed', 'Immediate surgery for all', 'Antibiotics only', 'No treatment',
'B', 'Benign GOO management: (1) Initial: NG tube decompression, IV fluids/electrolyte replacement, PPI, nutritional support (TPN if prolonged), (2) Trial of conservative therapy (resolves edema from active ulcer), (3) Endoscopic balloon dilation for strictures (may need repeated), (4) Surgery if failed medical/endoscopic therapy: pyloroplasty, gastrojejunostomy, or antrectomy with vagotomy (if PUD). Malignant: palliative gastrojejunostomy or stenting. Reference: Shone DN. Am J Gastroenterol. 1995.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Gastric volvulus is:',
'Normal anatomy', 'Abnormal rotation of the stomach on itself, causing closed-loop obstruction', 'A type of ulcer', 'Infection', 'Hemorrhage',
'B', 'Gastric volvulus: stomach rotation causing closed-loop obstruction. Types: (1) Organoaxial (59%) - rotation along long axis (cardia/pylorus), greater curvature rotates anteriorly, (2) Mesenteroaxial (29%) - rotation perpendicular to long axis (lesser/greater curvature), (3) Combined. Causes: diaphragmatic defects (paraesophageal hernia), ligamentous laxity. Borchardt triad (acute): severe epigastric pain, retching without vomiting, inability to pass NG tube. CXR: gastric distention. Treatment: acute - detorsion/gastropexy ± hernia repair; chronic - elective repair. Reference: Rashid F. World J Emerg Surg. 2010.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Borchardt triad, classic for acute gastric volvulus, consists of:',
'Fever, leukocytosis, pain', 'Severe epigastric pain, retching without vomiting, and inability to pass NG tube', 'Diarrhea, vomiting, dehydration', 'Headache, nausea, dizziness', 'Cough, dyspnea, chest pain',
'B', 'Borchardt triad (acute gastric volvulus): (1) Severe epigastric/chest pain (sudden onset), (2) Retching without productive vomiting (closed-loop obstruction), (3) Inability/difficulty passing NG tube (obstruction at GE junction or pylorus). May have: distention, hematemesis (ischemia), shock. Imaging: CXR/CT - distended, rotated stomach, "upside-down stomach". Emergency: resuscitation, NG decompression (if possible), surgery (detorsion, gastropexy, repair hernia). Reference: Rashid F. World J Emerg Surg. 2010.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Menetrier disease is characterized by:',
'Gastric atrophy', 'Giant gastric rugal folds, protein-losing gastropathy, and hypochlorhydria', 'Normal stomach', 'Increased acid', 'Cancer always',
'B', 'Menetrier disease (hypertrophic gastropathy): rare. Giant gastric folds (body/fundus), foveolar hyperplasia, glandular atrophy. Results in: (1) Protein-losing gastropathy (hypoalbuminemia, edema), (2) Hypochlorhydria (loss of parietal cells), (3) Epigastric pain, nausea, weight loss. Endoscopy: giant folds. Biopsy to exclude malignancy/lymphoma. Association with CMV (children), H. pylori. Small cancer risk (<10%). Treatment: supportive, H. pylori eradication, antisecretory, cetuximab (anti-EGFR). Severe: gastrectomy. Reference: Coffey RJ. Gastroenterology. 2012.',
'hard', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Dieulafoy lesion is:',
'A type of cancer', 'An abnormally large submucosal artery that erodes through mucosa causing significant GI bleeding', 'Normal finding', 'An ulcer', 'A polyp',
'B', 'Dieulafoy lesion: dilated aberrant submucosal artery (1-3mm, normally 0.1mm) that erodes through mucosa without significant ulceration. Cause of 1-2% of acute upper GI bleeds. Location: usually proximal stomach (lesser curvature, within 6cm of GE junction), can occur throughout GI tract. Presents with intermittent, massive, painless GI bleeding. Diagnosis challenging (small mucosal defect, intermittent bleeding). Endoscopy: visible vessel, minimal ulceration. Treatment: endoscopic hemostasis (clips, thermal, injection), surgery if refractory. Reference: Baxter M. Dig Dis Sci. 1990.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Gastric polyps are most commonly:',
'Malignant', 'Fundic gland polyps (benign, associated with PPI use) or hyperplastic polyps', 'Always adenomatous', 'Require gastrectomy', 'Symptomatic',
'B', 'Gastric polyps: (1) Fundic gland polyps (47%) - most common, benign, fundus/body, associated with PPI use or FAP, no malignant potential (except FAP), (2) Hyperplastic polyps (40%) - benign, but associated with atrophic gastritis/H. pylori, small cancer risk (<2%), (3) Adenomatous polyps (7%) - premalignant, especially >2cm. Management: biopsy, remove adenomatous/large (>1cm) polyps, H. pylori eradication for hyperplastic. Surveillance for adenomas. Reference: Carmack SW. Arch Pathol Lab Med. 2009.',
'medium', 'knowledge'),

('c0000042-0000-0000-0000-000000000042', 'a0000003-0000-0000-0000-000000000003',
'Zollinger-Ellison syndrome results from:',
'Insulin-producing tumor', 'Gastrin-secreting tumor (gastrinoma) causing severe peptic ulcer disease', 'Glucagon excess', 'Normal physiology', 'Thyroid disorder',
'B', 'Zollinger-Ellison syndrome: gastrin-secreting tumor (gastrinoma), usually pancreatic (70%) or duodenal (25%). Excess gastrin → acid hypersecretion → severe/refractory PUD (multiple ulcers, distal duodenum/jejunum), diarrhea (acid), GERD. Associated with MEN1 (25%). Diagnosis: fasting gastrin >1000 pg/mL (highly suggestive), or secretin stimulation test (paradoxical gastrin increase). Localization: CT/MRI, endoscopic ultrasound, somatostatin receptor scintigraphy. Treatment: high-dose PPI, surgical resection if localized, somatostatin analogs. Reference: Jensen RT. N Engl J Med. 1983.',
'medium', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 27 (Gastric Disorders): 60 questions inserted' as status;
